3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Ovarian Neoplasms
33
Breast Neoplasms
26
Triple Negative Breast Neoplasms
17
Prostatic Neoplasms
16
Fallopian Tube Neoplasms
11
Neoplasms
9
Fanconi Anemia, Complementation Group D1
7
Endometrial Neoplasms
7
Pancreatic Neoplasms
6
Glioma
6
Carcinoma, Ovarian Epithelial
6
Stomach Neoplasms
5
Small Cell Lung Carcinoma
5
Sarcoma
5
Neoplasm Metastasis
5
Cholangiocarcinoma
5
Uterine Cervical Neoplasms
4
Urinary Bladder Neoplasms
4
Lymphoma, Non-Hodgkin
4
Carcinoma, Non-Small-Cell Lung
4
Advanced Breast Cancer
4
Squamous Cell Carcinoma of Head and Neck
3
Recurrence
3
Osteosarcoma
3
Lung Neoplasms
3
Glioblastoma
3
Colorectal Neoplasms
3
Carcinosarcoma
3
Carcinoma, Renal Cell
3
Wilms Tumor
2
Interventions
Gemcitabine
9
Carboplatin
8
Paclitaxel
6
Capecitabine
4
Bevacizumab
4
pembrolizumab
3
Irinotecan
3
Erlotinib Hydrochloride
3
atezolizumab
2
Peripheral Blood Stem Cell Transplantation
2
Oxaliplatin
2
Filgrastim
2
Cisplatin
2
CP protocol
2
tislelizumab
1
tegafur-gimeracil-oteracil
1
spartalizumab
1
sintilimab
1
pertuzumab
1
pemigatinib
1
olaparib
1
ivosidenib
1
ipatasertib
1
etoposide phosphate
1
entrectinib
1
cobimetinib
1
belinostat
1
antineoplaston AS 2-1
1
antineoplaston A10
1
alectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasms, Unknown Primary
×
olaparib
×
Clear all
NCT03498521
2025-11-19
CUPISCO
Hoffmann-La Roche
Phase 2
Completed
529 enrolled
16 charts